Claire Dearden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Claire Dearden has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Catovsky
Division of Molecular Pathology, The Institute of Cancer Research, London, UK
2 shared publications - Estella Matutes
Royal Marsden Hospital
2 shared publications - Alan Ashworth
The Institute of Cancer Research, London, United Kingdom
1 shared publication - Alan Mackay
Division of Molecular Pathology, the Institute of Cancer Research, London SW7 3RP, UK
1 shared publication Chris Jones
Section of Paediatric Oncology, The Institute of Cancer Research (ICR), Sutton, Surrey, London, UK
1 shared publication- Dalemari Crowther-Swanepoel
Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
1 shared publication
Latest Publications
- 15 June 2008
- Published by American Society of Hematology in Blood
- Vol. 111 (12) , 5691-5693
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL
To address the proposition that familial B-cell chronic lymphocytic leukemia (CLL) may exhibit a more restricted phenotype than sporadic CLL with respect to immunoglobulin gene usage or ontogenic development, we compared immunoglobulin (Ig) heavy chain variable region (VH) gene usage and IgVH mutation status in 327 patients with CLL from 214 families with 724 patients with sporadic cases. The frequency of mutated CLL was higher in familial CLL (P < .001), and there was evidence of intrafamilial concordance in mutation status (P < .001). The repertoire and frequency of IgVH usage was, however, not significantly different between familial and sporadic CLL. Furthermore, IgVH usage was not correlated between affected members of the same family. These observations provide evidence that familial CLL is essentially indistinguishable from sporadic CLL, favoring a genetic basis to disease development in general rather than a simple environmental etiology.
- 15 June 2008
- Published by American Society of Hematology in Blood
- Vol. 111 (12) , 5691-5693
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL
To address the proposition that familial B-cell chronic lymphocytic leukemia (CLL) may exhibit a more restricted phenotype than sporadic CLL with respect to immunoglobulin gene usage or ontogenic development, we compared immunoglobulin (Ig) heavy chain variable region (VH) gene usage and IgVH mutation status in 327 patients with CLL from 214 families with 724 patients with sporadic cases. The frequency of mutated CLL was higher in familial CLL (P < .001), and there was evidence of intrafamilial concordance in mutation status (P < .001). The repertoire and frequency of IgVH usage was, however, not significantly different between familial and sporadic CLL. Furthermore, IgVH usage was not correlated between affected members of the same family. These observations provide evidence that familial CLL is essentially indistinguishable from sporadic CLL, favoring a genetic basis to disease development in general rather than a simple environmental etiology.
- 1 January 2008
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (10) , 1879-1886
Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescencein situhybridisation and array-based comparative genomic hybridisation
Deletion of the TP53 gene on chromosome 17p13.1 is the prognostic factor associated with the shortest survival in CLL. We used array-based comparative genomic hybridisation (arrayCGH) to identify additional DNA copy number changes in peripheral blood samples from 74 LRF CLL4 trial patients, 37 with ≥5% and 37 without TP53-deleted cells. ArrayCGH reliably detected deletions on 17p, including the TP53 locus, in cases with ≥50%TP53-deleted cells detected by fluorescence in situ hybridisation, plus seven additional cases with deleted regions on 17p excluding TP53. Losses on chromosomal regions 18p and/or 20p were found exclusively in cases with ≥5%TP53-deleted cells (p < 0.001), 38% having one or both losses. The incidence of additional cytogenetic abnormalities, reflecting an increased chromosomal instability, was higher in ≥5%TP53-deleted cases (p = 0.02). In particular, amplification of 2p and deletion of 6q were both more frequent. Cases with >20%TP53-deleted cells had the worst prognosis in the LRF CLL4 trial.
- 1 January 2008
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (10) , 1879-1886
Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescencein situhybridisation and array-based comparative genomic hybridisation
Deletion of the TP53 gene on chromosome 17p13.1 is the prognostic factor associated with the shortest survival in CLL. We used array-based comparative genomic hybridisation (arrayCGH) to identify additional DNA copy number changes in peripheral blood samples from 74 LRF CLL4 trial patients, 37 with ≥5% and 37 without TP53-deleted cells. ArrayCGH reliably detected deletions on 17p, including the TP53 locus, in cases with ≥50%TP53-deleted cells detected by fluorescence in situ hybridisation, plus seven additional cases with deleted regions on 17p excluding TP53. Losses on chromosomal regions 18p and/or 20p were found exclusively in cases with ≥5%TP53-deleted cells (p < 0.001), 38% having one or both losses. The incidence of additional cytogenetic abnormalities, reflecting an increased chromosomal instability, was higher in ≥5%TP53-deleted cases (p = 0.02). In particular, amplification of 2p and deletion of 6q were both more frequent. Cases with >20%TP53-deleted cells had the worst prognosis in the LRF CLL4 trial.
- 1 December 2002
- Published by Wiley in Reviews in Clinical and Experimental Hematology
- Vol. 6 (4) , 435-448
Alemtuzumab in lymphoproliferate disorders
- 1 December 2002
- Published by Wiley in Reviews in Clinical and Experimental Hematology
- Vol. 6 (4) , 435-448
Alemtuzumab in lymphoproliferate disorders
- 1 January 2002
- Published by Springer Nature in Medical Oncology
- Vol. 19 (2S) , S27-S32
Alemtuzumab in T-Cell Malignancies
Alemtuzumab is a humanized monoclonal antibody directed against the CD52 antigen, which is abundantly expressed on all normal and most malignant T-lymphocytes. We summarize the results of our...
- 1 January 2002
- Published by Springer Nature in Medical Oncology
- Vol. 19 (2S) , S27-S32
Alemtuzumab in T-Cell Malignancies
Alemtuzumab is a humanized monoclonal antibody directed against the CD52 antigen, which is abundantly expressed on all normal and most malignant T-lymphocytes. We summarize the results of our...